NEW YORK, Nov. 15, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter delivers exclusive interviews with Dr. Eugene Seymour, CEO of NanoViricides, Inc. (OTCBB:NNVC); Dr. Belinda Tsao Nivaggioli, CEO of The Avicena Group, Inc. (OTCBB:AVGO); and Alan Ezrin, CEO of Bradmer Pharmaceuticals, Inc. (TSX:BMR). The audio interviews are available at www.WallStreetReporter.com.
Dr. Eugene Seymour, CEO of NanoViricides, Inc. (OTCBB:NNVC) tells Wall Street Reporter about the company's seven breakthrough anti-viral drugs. These drugs are the first to be designed to directly destroy viruses like HIV, Influenza, and E Bola. "I know it sounds like science fiction, but it seems to be working," Dr. Seymour comments.
Highlights Include:
-- The unlimited market potential for the unique virus-attacking
drug lineup.
-- The drugs' revolutionary strategy of destroying viral cell
walls.
-- The company's strategic alliances with various government
agencies, including the Vietnamese Ministry of Health and the
Walter Reade Army Institute in the United States.
Another pharmaceuticals company with significant government backing is The Avicena Group, Inc. (OTCBB:AVGO). CEO Dr. Belinda Tsao Nivaggioli tells us, "We are only touching on the tip of our IP portfolio and we actually have plenty of opportunity to expand beyond that."
Highlights Include:
-- The company's revolutionary method of regulating cellular
energy.
-- Funding from Government agencies and collaborations with
academic institutions such as Columbia University.
-- The current launch of The Avicena Group's new branded
product line, Nurigene.
Alan Ezrin, CEO of Bradmer Pharmaceuticals, Inc. (TSX:BMR), which also maintains partners in academia, tells us, "We're very proud of what we've accomplished in the last two years." He adds, "We're about to conduct the world's largest glioblastoma trial, with over 760 patients."
Highlights Include:
-- Bradmer's acquisition of the drug from Duke University.
-- The product's personalized medicine approach, with dosages
custom-tailored to patients based on their specific conditions.
-- The upcoming Phase III clinical trial.
The interviews are available at www.WallStreetReporter.com. Visitors can also download the interviews to their iPods or subscribe to the complete series of podcasts on Apple iTunes.
Wall Street Reporter (Est. 1843) is the premier source of investment information on global small-cap public companies in high-growth sectors. Through their magazines, special reports, web site, and conferences, WSR presents unique opportunities for discovering stocks before they appear on the radar of Wall Street and have become "must-attends" and "must-reads" for the "who's who" of the investment community.
About Bradmer Pharmaceuticals Inc.
Bradmer Pharmaceuticals Inc. (TSX:BMR) is a Toronto-based biopharmaceutical company. Having already raised $35 million, the company is fully funded and plans to begin the world's largest glioblastoma trial early next year.
About The Avicena Group, Inc.
The Avicena Group, Inc. (OTCBB:AVGO) is a biopharmaceuticals company with a dual focus on neurological and dermatological technologies. The company plans to have three drugs in Phase III testing by 1st Quarter of 2008.
About NanoViricides, Inc.
NanoViricides, Inc. (OTCBB:NNVC) is a biopharmaceuticals company operating in the antiviral arena. Currently, the company is developing seven antiviral drugs and moving quickly to file their revolutionary technologies with the FDA.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.